作者: 抵制 時間: 2025-3-22 00:17 作者: labile 時間: 2025-3-22 00:30 作者: 樹木心 時間: 2025-3-22 08:07 作者: GLOOM 時間: 2025-3-22 12:04
Hepatocellular Carcinoma: Surgical Management and Evolving Therapies,ing cause of cancer death worldwide, with 780,000 deaths in 2018. Seventy-two percent of HCC cases occur in Asia, 10% in Europe, 8% in Africa, 5% in North America, and 5% in Latin America (Singal et al. in J Hepatol 72(2):250–261, 2020 [.]).作者: BIAS 時間: 2025-3-22 13:26
Locoregional Therapies for Primary and Secondary Hepatic Malignancies,nt surgeons, and interventional radiologists. Patients should be selected for a specific targeted therapy after multidisciplinary consensus. Interventional oncology, with image-guided locoregional cancer therapies, can decrease systemic toxicity without compromising tumoricidal effect.作者: BIAS 時間: 2025-3-22 17:48
Gastrointestinal Malignancies978-3-031-61238-1Series ISSN 0927-3042 Series E-ISSN 2509-8497 作者: Fibroid 時間: 2025-3-23 00:12
Sraffa’s Lectures on Continental BankingNeuroendocrine neoplasms are a heterogeneous group of tumors that can occur in almost any organ and share a common neuroendocrine phenotype.作者: needle 時間: 2025-3-23 01:27 作者: Crohns-disease 時間: 2025-3-23 06:36
https://doi.org/10.1007/978-94-011-9447-1Colorectal cancer (CRC) is the third most commonly diagnosed cancer in men and women (Siegel et al. in CA Cancer J Clin 72(1):7–33). Over one-half of newly diagnosed individuals will develop liver metastases. Among those with liver-only metastatic disease, only about one in five will be candidates for potentially curable resection.作者: 最低點 時間: 2025-3-23 10:48 作者: 影響深遠 時間: 2025-3-23 16:45 作者: V洗浴 時間: 2025-3-23 20:08 作者: Abjure 時間: 2025-3-24 01:22 作者: 水槽 時間: 2025-3-24 03:26 作者: nonsensical 時間: 2025-3-24 09:59 作者: WAX 時間: 2025-3-24 13:26
Postmodernismus und Sri Aurobindoar survival benefit, neoadjuvant chemotherapy has gained interest due to its ability to prioritize the treatment of micrometastatic disease prior to resection and improve chemotherapy tolerance prior to a major operation. Investigations have focused on evaluating the survival benefit of neoadjuvant 作者: intertwine 時間: 2025-3-24 17:57
https://doi.org/10.1007/978-81-322-1904-0ection is more common among patients who undergo preoperative biliary instrumentation, likely because of the introduction of intestinal flora into the normally sterile biliary tree. Frequently, bacterial isolates from surgical site infections after pancreaticoduodenectomy demonstrate resistance to t作者: 單色 時間: 2025-3-24 20:08 作者: 間接 時間: 2025-3-25 01:11
,The Early History of St Hugh’s College,it represents approximately 3% of all gastrointestinal malignancies, though its global incidence is rising. CC can often be asymptomatic in its early stages and as a result, it is frequently diagnosed in later stages, leading to challenges in clinical management.作者: 解開 時間: 2025-3-25 03:43 作者: accomplishment 時間: 2025-3-25 10:58
,Interaction: the City’s Social Life,nt surgeons, and interventional radiologists. Patients should be selected for a specific targeted therapy after multidisciplinary consensus. Interventional oncology, with image-guided locoregional cancer therapies, can decrease systemic toxicity without compromising tumoricidal effect.作者: 剝皮 時間: 2025-3-25 14:45 作者: interlude 時間: 2025-3-25 19:02 作者: Aspiration 時間: 2025-3-25 23:32 作者: prosperity 時間: 2025-3-26 03:41 作者: 艱苦地移動 時間: 2025-3-26 04:54 作者: 知道 時間: 2025-3-26 09:34 作者: Employee 時間: 2025-3-26 15:26
Gastrointestinal Malignancies: Pancreatic Cancer Clinical Trials in Neoadjuvant Chemotherapy,ar survival benefit, neoadjuvant chemotherapy has gained interest due to its ability to prioritize the treatment of micrometastatic disease prior to resection and improve chemotherapy tolerance prior to a major operation. Investigations have focused on evaluating the survival benefit of neoadjuvant 作者: originality 時間: 2025-3-26 18:49 作者: MEN 時間: 2025-3-26 21:59
Gallbladder Cancer,es (Hundal and Shaffer in Clin Epidemiol 6:99–109, 2014 .; Henley et al. in Cancer Epidemiol Biomarkers Prev 24:1319–1326, 2015 .). The insidious nature and late presentation of this disease place it among the most lethal invasive neoplasms. Gallbladder cancer spreads early by lymphatic or hematogen作者: Spinal-Fusion 時間: 2025-3-27 03:40
Cholangiocarcinoma,it represents approximately 3% of all gastrointestinal malignancies, though its global incidence is rising. CC can often be asymptomatic in its early stages and as a result, it is frequently diagnosed in later stages, leading to challenges in clinical management.作者: Glutinous 時間: 2025-3-27 05:47 作者: peak-flow 時間: 2025-3-27 13:28 作者: 填料 時間: 2025-3-27 15:08
Pathologic Features of Primary Colon, Rectal, and Anal Malignancies,egel et al. in Cancer J Clin 73:1–112, 2023 [.]). Worldwide, colorectal cancer is the second leading cause of death and causes almost 916,000 deaths each year (Ferlay in Global cancer observatory: cancer today. International Agency for Research on Cancer, Lyon, 2020 [.]). Fortunately, due to the col作者: 替代品 時間: 2025-3-27 21:00 作者: 搬運工 時間: 2025-3-28 00:37
Gastrointestinal Malignancy: Genetic Implications to Clinical Applications,stinal (GI) cancers. This chapter provides a comprehensive overview of the molecular landscape of GI cancers, focusing on key genetic alterations implicated in tumorigenesis across various anatomical sites including GIST, colon and rectum, and pancreas. Emphasis is placed on critical oncogenic pathw作者: 刺穿 時間: 2025-3-28 03:17
The Cytoskeleton of the Squid Giant Axonved in about 10% of the cases. Hereditary gastric cancer accounts for a very low percentage of cases. Here we review the genetic and environmental risk factors associated with the disease. In addition, we will review screening guidelines and current modalities that are available for screening in high-risk populations.作者: achlorhydria 時間: 2025-3-28 09:58
Postmodernismus und Sri Aurobindotherapy using single and combination chemotherapy as well as radiation therapy. Landmark trials in localized pancreatic cancer have paved the way for the standard use of neoadjuvant therapy for pancreatic adenocarcinoma.作者: 同時發(fā)生 時間: 2025-3-28 12:27 作者: Recess 時間: 2025-3-28 17:53 作者: circuit 時間: 2025-3-28 19:46
Gallbladder Cancer,ous metastasis, as well as by direct invasion into the liver. While surgery may be curative at early stages, both surgical and nonsurgical treatments remain largely unsuccessful in patients with more advanced diseases (Rahman et al. in Cancer Med 6:874–880, 2017 .).作者: GROSS 時間: 2025-3-28 22:58
Environmental and Genetic Risk Factors for Gastric Cancer,ved in about 10% of the cases. Hereditary gastric cancer accounts for a very low percentage of cases. Here we review the genetic and environmental risk factors associated with the disease. In addition, we will review screening guidelines and current modalities that are available for screening in high-risk populations.作者: 枕墊 時間: 2025-3-29 03:08 作者: 瑣碎 時間: 2025-3-29 09:22 作者: 圓錐 時間: 2025-3-29 12:37 作者: conscribe 時間: 2025-3-29 15:57 作者: 現(xiàn)任者 時間: 2025-3-29 21:43 作者: GEM 時間: 2025-3-30 00:45
Gastrointestinal Malignancy: Genetic Implications to Clinical Applications,le of molecular biomarkers in predicting prognosis, guiding treatment decisions, and monitoring therapeutic response is discussed, highlighting the integration of genomic profiling into clinical practice. Finally, we address the evolving landscape of precision oncology in GI cancers, considering targeted therapies and immunotherapies.作者: mitral-valve 時間: 2025-3-30 04:21
Pathologic Features of Esophageal and Gastric Malignancies,pathologist when dealing with esophageal carcinoma that include rendering a diagnosis, classifying the histological type, and assessing prognostic factors. This narrative review aims to evaluate current literature on various esophageal neoplasms and highlight pathological factors that impact clinica作者: FIR 時間: 2025-3-30 11:24 作者: 玉米棒子 時間: 2025-3-30 13:51
Immunotherapy in Gastrointestinal Cancers,timing of surgery in patients who respond to immunotherapy, and toxicities specific to patients with gastrointestinal malignancies. We outline the current landscape and future horizon of immunotherapy in gastrointestinal cancers, such as strategies to increase effectiveness of checkpoint blockade th作者: 接合 時間: 2025-3-30 19:16 作者: 異教徒 時間: 2025-3-30 20:49
https://doi.org/10.1007/978-81-322-1904-0 the first U.S. randomized surgical trial to utilize a clinical registry for data collection, this study serves as proof of concept for registry-based clinical trials. The trial has successfully completed patient accrual, and study results are forthcoming.作者: FLACK 時間: 2025-3-31 04:25 作者: 容易生皺紋 時間: 2025-3-31 05:47
